LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Accueil・Liste d'Actions・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Fermé

SecteurSoins de santé

10.76 0.47

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.12

Max

10.86

Chiffres clés
By Trading Economics
Revenu	227M
Ventes	139M
P/E Moyenne du Secteur	4.302 49.888
Marge bénéficiaire	163.843
Employés	1,796
EBITDA	1.3M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+54.84% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	2B
Ouverture précédente	10.29
Clôture précédente	10.76

Sentiment de l'Actualité

By Acuity

10%

90%

11 / 344 Classement par Healthcare

Hutchison China MediTech Ltd ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 juin 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 juin 2026, 15:41 UTC

Principaux Mouvements du Marché

American Battery Shares Jump on Energy Department Victory

8 juin 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 juin 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 juin 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 juin 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 juin 2026, 21:57 UTC

Acquisitions, Fusions, Rachats

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 juin 2026, 21:56 UTC

Acquisitions, Fusions, Rachats

Salesforce Agrees to Buy m3ter

8 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 juin 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 juin 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 juin 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 juin 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 juin 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 juin 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 juin 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 juin 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 juin 2026, 16:55 UTC

Acquisitions, Fusions, Rachats

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 juin 2026, 16:54 UTC

Acquisitions, Fusions, Rachats

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 juin 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 juin 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 juin 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 juin 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 juin 2026, 16:03 UTC

Acquisitions, Fusions, Rachats

Orange Bought Stake From Lorca

8 juin 2026, 16:01 UTC

Acquisitions, Fusions, Rachats

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 juin 2026, 16:01 UTC

Acquisitions, Fusions, Rachats

Orange Acquires 100% Ownership of MasOrange

8 juin 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 juin 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 juin 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 juin 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparaison

Variation de prix

Hutchison China MediTech Ltd ADR prévision

Objectif de Prix

By TipRanks

54.84% hausse

Prévisions sur 12 Mois

Moyen 16.8 USD 54.84%

Haut 20 USD

Bas 13.6 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

Achat

Maintien

Vente

Basé sur 2 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

11 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.